Thalomid thalidomide: Phase II data; marketed to treat cutaneous manifestations of erythema nodosum leprosum (ENL)

In a 169-patient Phase II trial, 30 percent of patients had a >50 percent reduction in paraprotein levels (abnormal immunoglobulin production by myeloma cells), with 14 percent of these patients exper...